- Home
- JXG vs NLSP Comparison
JXG vs NLSP Comparison
Compare JXG & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- NLSP
- Stock Information
- Founded
- JXG N/A
- NLSP 2015
- Country
- JXG China
- NLSP Switzerland
- Employees
- JXG N/A
- NLSP N/A
- Industry
- JXG
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- NLSP Health Care
- Exchange
- JXG Nasdaq
- NLSP Nasdaq
- Market Cap
- JXG 10.4M
- NLSP 12.4M
- IPO Year
- JXG N/A
- NLSP 2021
- Fundamental
- Price
- JXG $0.85
- NLSP $1.92
- Analyst Decision
- JXG
- NLSP
- Analyst Count
- JXG 0
- NLSP 0
- Target Price
- JXG N/A
- NLSP N/A
- AVG Volume (30 Days)
- JXG 1.8M
- NLSP 934.7K
- Earning Date
- JXG 05-15-2025
- NLSP 10-06-2025
- Dividend Yield
- JXG N/A
- NLSP N/A
- EPS Growth
- JXG N/A
- NLSP N/A
- EPS
- JXG 0.86
- NLSP N/A
- Revenue
- JXG $49,840,288.00
- NLSP N/A
- Revenue This Year
- JXG N/A
- NLSP N/A
- Revenue Next Year
- JXG N/A
- NLSP N/A
- P/E Ratio
- JXG $1.03
- NLSP N/A
- Revenue Growth
- JXG 56.53
- NLSP N/A
- 52 Week Low
- JXG $0.55
- NLSP $1.30
- 52 Week High
- JXG $7.72
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- JXG 44.39
- NLSP 44.35
- Support Level
- JXG $0.71
- NLSP $2.00
- Resistance Level
- JXG $0.92
- NLSP $2.15
- Average True Range (ATR)
- JXG 0.10
- NLSP 0.21
- MACD
- JXG 0.01
- NLSP -0.01
- Stochastic Oscillator
- JXG 38.65
- NLSP 22.86
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.